Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product
This article was originally published in Scrip
Basilea Pharmaceutica's ceftobiprole was designated by the FDA as a qualified infectious disease product – a status under which the drug is eligible for an additional five years of market exclusivity if approved for the indications.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.